Embol-X U.S. launch
This article was originally published in The Gray Sheet
Executive Summary
185-patient study at Goethe Universitat in Frankfurt shows that Embol-X reduces cerebral injury 74% in high-risk patients compared to procedures without the filter, Edwards notes in materials for U.S. launch of aortic embolic protection device, announced Aug. 20. Edwards acquired the device through its $10 mil. purchase of Embol-X, Inc. in May (1"The Gray Sheet" May 5, 2003, p. 24). Embol-X is the only aortic embolic protection device approved in the U.S. for use during cardiac surgery, the company claims...
You may also be interested in...
Edwards Enters Embolic Filtration Market With Embol-X Technology
Edwards Lifesciences will offer embolic filtration technology developed by Embol-X, Inc. for use during open-heart procedures such as valve replacement under an asset purchase valued at about $10 mil
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.